HER2

Post ASCO Update on Management of HER2+ Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Tanios S. Bekaii-Saab, MD
An Update on the role of ctDNA-MRD Assessment in The Management of Breast Cancer

Jason A. Mouabbi, MD
What is the optimal approach to targeting BRAF V600E, HER2 overexpression, and KRAS G12C in patients with metastatic CRC?

John Strickler, MD
Current and Evolving Approaches for HER2+ Breast Cancer Brain Metastases

Carey Anders, MD
Current and Evolving Approaches for HER2+ Breast Cancer Brain Metastases

Carey Anders, MD
Management of HER2+ Breast Cancer Brain Metastases

Sarah Sammons, MD
Advances in the Management of Colorectal Cancer: Recent Evidence and Emerging Treatment Paradigms

John Strickler, MD
Evolving Treatment Landscape for HER2 Positive Gastroesophageal Adenocarcinoma

John Strickler, MD
Recent Advances in the Treatment of Advanced HER2+ GEJ Cancers

Tanios S. Bekaii-Saab, MD
Update on the Evolving Management of Metastatic HER2- Expressing Breast Cancer

Adrienne G. Waks, MD
Residual Risk in HER2+ Disease: Rethinking pCR, Recurrence, and CNS Protection

Jason A. Mouabbi, MD
Implementing HER2-Targeted Strategies for the Treatment of Biliary Tract Cancers

John Strickler, MD; Tanios S. Bekaii-Saab, MD